Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
Prostate cancer and prostatic diseases（2023）
摘要
AA + P treatment without ADT may be effective in mCRPC patients and ADT may not be necessary in patients receiving AA + P.
更多查看译文
关键词
Cancer therapy,Prostate cancer,Biomedicine,general,Cancer Research,Reproductive Medicine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要